

Adenosine A2B receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/AF61DC532380EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: AF61DC532380EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Adenosine A2B receptor antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Adenosine A2B receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Adenosine A2B receptor antagonists Understanding

Adenosine A2B receptor antagonists: Overview

Adenosine is generated mainly via the degradation of adenosine 5'-triphosphate (ATP) released under stress conditions, to protect cells and tissues locally. Adenosine and ATP acting at different classes of receptors often have opposite effects in cell proliferation or cell death. ATP and other adenine nucleotides have antitumor effects via the activation of the P2Y1 receptor (P2Y1R) subtype, whereas adenosine induces cancer cell proliferation and growth of many types of tumors via the activation of the A2B adenosine receptor (AR) .

A2BAR activation leads to dissociation of the G β s and G γ subunits and subsequent activation of the adenylyl cyclases, which in turn hydrolyze intracellular ATP into cyclic AMP (cAMP), which activates protein kinase A (PKA) and many downstream signaling molecules. The Gs-cAMP-PKA axis is an important A2BAR-mediated signaling pathway.

A2BAR signaling is a major pathway contributing to cancer cell proliferation and solid tumor growth, angiogenesis and metastasis, and immune suppression. Thus, A2BAR antagonists are potentially a novel anticancer therapy, either in combination with other anticancer drugs or as a mono-therapy.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Adenosine A2B receptor antagonists R&D. The therapies under development are focused on novel approaches for Adenosine A2B receptor antagonists.

Adenosine A2B receptor antagonists Emerging Drugs Chapters

This segment of the Adenosine A2B receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Adenosine A2B receptor antagonists Emerging Drugs

Etrumadenant: Arcus Biosciences

Etrumadenant (AB928), the dual A2a/A2b adenosine receptor antagonist, designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8⁺ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR, respectively.

A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS-mutated cancers. As a result, etrumadenant may uniquely block adenosine's

immunosuppressive and cancer cell-intrinsic effects.

It is currently in Phase II stage of development and is being developed by Arcus Biosciences.

Further product details are provided in the report.....

Adenosine A2B receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Adenosine A2B receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Adenosine A2B receptor antagonists

There are approx. 7+ key companies which are developing the Adenosine A2B receptor antagonists. The companies which have their Adenosine A2B receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, Arcus Biosciences.

Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Adenosine A2B receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Adenosine A2B receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adenosine A2B receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenosine A2B receptor antagonists drugs.

Adenosine A2B receptor antagonists Report Insights

- Adenosine A2B receptor antagonists Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Adenosine A2B receptor antagonists Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Adenosine A2B receptor antagonists drugs?

How many Adenosine A2B receptor antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Adenosine A2B receptor antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenosine A2B receptor antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Adenosine A2B receptor antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Palbiofarma

Arcus Biosciences

Incyte Corporation

Teon Therapeutics

Corvus Pharmaceuticals

Tarus Therapeutics

AdoRx Therapeutics

Key Products

PBF-1129

Etrumadenant

INCB106385

TT-702

CPI-935

TT-4

Research Programme: A2A/A2B receptors antagonists

Contents

- Introduction
- Executive Summary
- Adenosine A2B receptor antagonists: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Drug Name: Company Name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Etrumadenant: Arcus Biosciences
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- INCB106385: Incyte Corporation
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Preclinical and Discovery Stage Products
 - Comparative Analysis

CPI-935: Corvus Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Adenosine A2B receptor antagonists Key Companies

Adenosine A2B receptor antagonists Key Products

Adenosine A2B receptor antagonists- Unmet Needs

Adenosine A2B receptor antagonists- Market Drivers and Barriers

Adenosine A2B receptor antagonists- Future Perspectives and Conclusion

Adenosine A2B receptor antagonists Analyst Views

Adenosine A2B receptor antagonists Key Companies

Appendix

I would like to order

Product name: Adenosine A2B receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/AF61DC532380EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF61DC532380EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970